Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPI-326 in Advanced EGFR-Mutant NSCLC and HNSCC
NCT07462377Phase 1Recruiting
- Sponsor
- EpiBiologics
- Start
- Mar 2026
- Primary completion
- Jul 2029
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of EPI-326 in non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), sponsored by EpiBiologics. Primary endpoints: Evaluation of the safety and tolerability of EPI-326 up to 3 years and Determination of the recommended dose and schedule for EPI-326 administration up to 3 years. Started Mar 2026; status: recruiting.
02
Drugs
EPI-326
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07462377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07462377.